Roche Holding AG said on Wednesday three studies on its drugs used to treat early and advanced breast cancer showed good results.
The Swiss drugmaker, the world's largest maker of cancer drugs, was due to present the results in coming days at the San Antonio Breast Cancer Symposium.
Roche said it would present five-year follow-up data from two studies into the use of Herceptin in early breast cancer which sought to answer questions about the best way of giving patients the treatment.
It will also present a study into the use of Avastin as a second-line treatment of advanced breast cancer.
Finally, it is also presenting new data from a Phase II study into the use of trastuzumab-DM1 for very advanced breast cancer.